Mad Hedge Technology Letter
November 22, 2019
Fiat Lux
Featured Trade:
(THE REAL STORY BEHIND THE CHARLES SCHWAB/TD AMERITRADE MERGER),
(SCHW), (AMTD), (ETFC), (IBKR)
Mad Hedge Technology Letter
November 22, 2019
Fiat Lux
Featured Trade:
(THE REAL STORY BEHIND THE CHARLES SCHWAB/TD AMERITRADE MERGER),
(SCHW), (AMTD), (ETFC), (IBKR)
There are certain parts of tech that I routinely bash on like travel tech, music streaming tech, and the usefulness of social media companies.
One other group of companies that I’m just as sour on are the discount e-brokers.
Yes, tech has embedded deflation into every company causing operations to become more efficient while boosting performance.
That doesn’t necessarily translate into more sales for some, and they have cut down the barriers of entry to e-brokers who have struggled.
The race down to zero finally hit rock bottom a few months ago when Interactive Brokers (IBKR) announced doing away with trading fees.
Buying and selling stocks and ETFs now costs the consumer nothing and this has been great news for investors and traders who don’t need to shoulder the extra trading costs.
But what about the e-brokers themselves?
Today Charles Schwab (SCHW) announced they are in negotiations to buy out the smaller TD Ameritrade (AMTD).
This was due to happen and is just another round of an industry-wide reshuffle.
I have never once thought these e-broker companies were a candidate for a tech alert, there are so many better companies out there.
Smaller commissions mean less revenue and the exact opposite of what investors should hope for in a tech company.
The lack of pricing power stems from the issue that e-brokers offer a commodified service of selling standard products and pricing is the only way to differentiate themselves.
The first startup company to offer zero was Menlo Park, California dark horse Robinhood which was recently valued at $7.6 billion.
They make money on the interest from customer deposits and sell data flow to high-frequency traders who in turn monetize the numbers using faster internet connections.
The spirited startup was found in 2013 and has added over 6 million users who are mostly from the Millennial age group.
These 6 million also represent the numbers lost to the discount e-brokers.
Robinhood’s influence in the industry cannot be understated as they singlehandedly forced an e-broker to cut commissions one by one blowing up their business model.
E-brokers had no choice but to cut to zero unless they were content to bleed customers.
Don’t forget that TD Ameritrade acquired competitor Scottrade just two years ago as the consolidation merry-go-round began.
The Schwab and TD Ameritrade deal will create over $5 trillion in asset management together.
Moving forward, the big question is how can these companies sustain themselves.
Exactly, there appears to be no panacea and I would recommend any investor to avoid investing in these e-brokers.
Schwab appears to be hanging their hat on their additional financial services they will be able to provide customers like offering mutual funds.
In addition to offering online brokerage accounts and robo-advisor services, Schwab and TD Ameritrade play a pivotal role in the independent advisory space because they custody assets and offer related services to RIAs.
According to Financial Advisor magazine, Schwab is the leading RIA custodian, and TD Ameritrade ranks third after Fidelity.
A merged company can theoretically offer more services to RIAs, but could also create opportunities for others.
Could these services become a race down to zero as well?
Disruption is in the early innings and round two could see Interactive Brokers or E*Trade (ETFC) in the next round of consolidation.
Smaller e-brokers will in time go bust or get bought out.
This reaffirms the broad trend of financial jobs eroding rapidly as the onslaught of technology has made certain jobs obsolete.
U.S. financial jobs are set to slide by 10% in the upcoming years.
Back office bank jobs are disappearing as we speak and the next big wave of job losses after that will be the front-office broker.
Yes, your Schwab broker could become an algorithm.
At some point, there will be a few managers left over, a handful of executives, and an army of software engineers.
“I am so disturbed by kids who spend all day playing videogames.” – Said Co-Founder and CEO of Oracle Larry Ellison
Global Market Comments
November 22, 2019
Fiat Lux
Featured Trade:
(TRADING THE KENNEDY ASSASSINATION)
While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more
Global Market Comments
November 21, 2019
Fiat Lux
SPECIAL TESLA ISSUE
Featured Trade:
(TESLA TALES), (TSLA)
When a guest asked me to name a clear ten bagger stock for the coming decade at the Mad Hedge Technology Letter, I didn’t hesitate. It was Tesla (TSLA).
At long last, investors are perking up and taking notice of the Fremont, California based electric car manufacturer whose shares have been trapped in a highly volatile three-year trading range.
Tesla was the top-performing stock in the market over the last five months, soaring some 96% from $178 to $356.
Of course, ramping up production to over 360,000 units this year has given Tesla new respectability. Elon Musk pulled this off by building a huge tent in the Tesla Fremont parking lot and constructing a third assembly line, all in three short weeks.
He also used workers to replace the German Kuka and Japanese Fanuc robots which had a bad habit of breaking down during peak production. Output instantly leaped by 50%. It was one of the most aggressive and brilliant moves in business history.
Total production of Tesla’s since the 2010 inception of Model S-1 manufacturing will reach 1 million by January 2020.
They are also encouraged by the appointment of Larry Ellison to the board of directors, a new supervising adult and Musk friend. The short answer is that they will go up a lot, certainly after they break through the old $394 high.
I was one of the first buyers of Tesla shares at $16 ½ in the aftermath of its IPO debacle during the Great Recession. I bought one of the first Tesla Model S-1’s, chassis no. 125, in 2011.
I’ve toured the Fremont factory countless times and have even taken a couple apart after I totaled them. Suffice it to say that I know which end of a Tesla to hold upwards.
So it’s time for all of us to become more familiar with this vehicle that is 20 years from the future. I have been driving the latest Model X with every possible upgrade for the past year, which included the hardware for the point-to-point autopilot that will be activated in two years.
What I learned was amazing.
While the media focus is overwhelmingly on the 1,100-pound liquid-cooled lithium-ion battery, it is fact one of the least important aspects of Elon Musk’s vision.
The car has 80% fewer parts than any other modern vehicle. That enables Tesla to cut production costs to the extent that it can afford to install a $10,000 battery in every Model 100D shipped.
And here’s the interesting part. Since I started driving electric cars 11 years ago with the Nissan Leaf, the battery cost has cratered from $1,000 to $120 per kilowatt-hour. With the completion of the second Gigafactory in Sparks, NV, that cost will drop well below $100/kWh. That’s what will make Tesla’s low-end Tesla 3 to become profitable….and go global.
I am constantly learning new things about these elegant, well thought out machines. When I picked up my last one, the configuration was all wrong. No problem. After 30 minutes in the shop, it came back to the specifications I ordered.
It was then I realized that all the options and upgrades are modular and can be snapped, fitted, or screwed on in minutes. That greatly simplified production, distribution, and versatility.
The downside is that Tesla is expanding so fast that the man who sold it to me knew virtually nothing about the car, being a former Mercedes salesman, and REGISTERED THE CAR IN THE WRONG STATE. But then it’s tough to find any good people today in this full-employment economy.
Ever the scientist, I designed a series of grueling experiments to put my “X” through during my Christmas vacation at Lake Tahoe.
I was able to make the 200 miles from the San Francisco Bay Area to Lake Tahoe on a single charge, a vertical climb of 7,200 feet. Better to stop at the Safeway in Truckee, CA which offers 16 superchargers, do your grocery shopping, and get a top-up.
Having flown small aircraft across the Atlantic, I am somewhat sensitive to range considerations. I once flew a Cessna 340 from Newfoundland to Iceland. Over Greenland, the wind shifted from a 50 miles tailwind to a 50 miles headwind, but we didn’t know it because GPS was not yet available to civilians. I ended up landing in Reykjavik with 15 minutes of fuel. An Icelandic Air Force helicopter escorted me the last 20 miles as a precaution.
And by the way, it is impossible to put on an orange survival floatation suite while you’re flying a plane. But I diverge.
I drove from the Tesla Supercharger station at the Atlantis Hotel & Casino in Reno, NV to my home in Incline Village, a distance of 30 miles. That meant crossing the Mount Rose Pass, a climb of 5,000 feet at zero degrees Fahrenheit. The “X” burned through 80 miles of range. The black ice was a killer, and I passed three accidents.
However, when I made the return trip, the vehicle used only 20 miles of range. That’s because each of the four wheels is a dynamo that recharges the battery on any decline. The car is in effect gravity-powered.
There has also been a lot of media fascination with the autopilot. Because of the three fatal crashes, its use has been cut back by Tesla to one minute at a time. You have to grip the wheel to reactivate it to prove you haven’t fallen asleep. After a while, your fingers get sore. Still, it’s useful to make phone calls or search Slacker for new music while you're driving. And the car certainly drives better than I can late at night after a bottle of fine cabernet.
Still, Bay Area police are arresting Tesla drivers found dozing at the wheel driving 70 mph. Maybe it’s those punishing Silicon Valley hours that’s doing it.
Far more useful is the radar-controlled cruise control. The car will automatically slow down when it catches up with the car in front. The problem is that at my advanced age, I can’t remember if I’m on autopilot or cruise control. I only find out when the car starts to drift over into the next lane.
A foot of fresh powder at Tahoe allowed me to test out the four-wheel-drive traction. It did fine driving up steep Sierra mountains. The all-season Pirelli Scorpion tires lived up to their billing, neatly handling an inch of clear ice on a 15-degree slope.
I learned a lot about electric cars, in general, hanging out at the ChargePoint station at the Diamond Peak Ski Resort where they offer free charging. Virtually all other competing cars only have an 80-mile range for the same price despite what their advertising says. A lot of businesses are now offering this service to lure high-end clientele, but you need a ChargePoint membership card to access the charging system.
Tahoe was a great place to test out the cold weather capability of the X where temperatures frequently can drop below zero degrees Fahrenheit at night. If you start the car cold in the morning, you’ll lose 50% of your range right off the bat.
However, if you pre-heat your car 20 minutes ahead of time by activating a handy iPhone app the loss only drops to 20% of the 295 miles range. It’s best to trickle charge the car all night at 20 watts/hour.
Playing with the 12-sensor radar is fun, whizzing past cars and trucks on the display as you pass them. It recognized my tail hitch mounted ski rack as a tailgating motorcycle. Apparently, algorithms don’t know everything….yet.
And here’s Tesla’s dirty little secret. All of the Model X’s and S’s have the same identical battery back. The ranges for the cheaper 60 and 70 kWh models are only software limited. That’s how Tesla instantly extended the range of every vehicle in Florida by 50 miles with a single command from headquarters with the onset of Hurricane Michael.
We’ll all be learning a lot more about Tesla soon. The $37,000 stripped-down Tesla 3’s are now for sale at the same price but three times the range and vastly more manufacturing experience than other electric vehicles. Sometimes they offer free charging for life.
That's when Tesla’s will truly take over the roads.
Mad Hedge Biotech & Healthcare Letter
November 21, 2019
Fiat Lux
Featured Trade:
(WHY VERTEX HAS BEEN ON FIRE),
(VRTX), (CRSP)
Vertex Pharmaceuticals Inc. (VRTX) is the unequivocal king of the genetically rare lung condition cystic fibrosis (CF). To further prove its stronghold of the market, the company recently received FDA approval for its fourth CF treatment called Trikafta — five full months ahead of schedule and merely three months following the company’s application.
In a few weeks, the drug will be available in pharmacies, carrying a price tag of $311,000. This puts Trikafta somewhere in the range of another prized Vertex CF treatment, Kalydeco.
Sales of this newest drug is estimated to reach $4.6 billion by 2023 and more than $6.6 billion by 2025, with the drug projected to hit its peak at $10 billion by the second half of 2020. Hence, this latest addition to Vertex’s pipeline practically guarantees the company’s supremacy over the lucrative multi-billion dollar sector for the next decade or so. More importantly, sales from this CF drug could — at the very least — double the annual revenue of Vertex.
The projected earnings of Trikafta places it in the blockbuster tier as early as 2020, with the drug anticipated to be marketed as a treatment with a “whole new level” of efficacy compared to the earlier CF medications released by Vertex. With this new addition, the company can now reach 90% of CF patients in the United States — a huge leap from 50% it’s currently allowed to treat.
However, the launch of Trikafta is a bittersweet deal with Vertex as sales of older treatments are anticipated to weaken. In particular, the company expects Symdeko and Orkambi to eventually fade away from the market as more and more patients opt for the newer and more potent Trikafta.
Despite the impending success of Trikafta, it appears that Vertex has no intention of letting up. Since its CF products have translated into healthy profits in the past four quarters and a whopping $950 million in the third quarter alone, it’s no wonder the company continues to work on new offerings for this market.
Even with the weakening sales of Symdeko, the performance of the CF drugs in the most recent earnings report showed a 21% jump over the same period in 2018. To date, the company has three additional treatments submitted for Phase II trials.
Beyond the CF realm, Vertex has also been looking to expand in other sectors. One of its exciting partnerships is with gene-editing company CRISPR Therapeutics (CRSP). The two companies have been working closely to come up with game-changing treatments that could pioneer therapies for rare conditions like sickle cell disease, Duchenne muscular dystrophy, and beta thalassemia. All three of these orphan designation drugs have the potential to turn into blockbuster treatments.
For 2019, Vertex projects a product revenue somewhere between $3.70 billion to $3.75 billion. Meanwhile, its full-year earnings per share is estimated to be $4.77, which is a 17% increase from last year’s report.
A clear downside of Vertex is the fact that it’s one of the most highly valued stocks in the biotech industry at 31.1 times forward earnings. Nonetheless, a long-term study of the company’s performance would show that the shares are actually grossly undervalued even at their present-day levels. After all, this biotech stock has the potential to triple or even quadruple its yearly revenue over the next five years or so especially if its partnership with CRISPR Therapeutics comes into fruition.
Overall, the growth and profitability profile of Vertex makes it an attractive stock to own. Add to that its promising pipeline, and you have one of the most attractive names in the biotech sector. Hence, now is the ideal time for investors to buy Vertex shares as you can confidently bet on its dominance on the CF market as well as its exciting gene-editing ventures and potential revenue stream.
Don’t chase Vertex up here but buy the next substantial dip.
“Humans are vastly underestimated,” said Tesla founder Elon Musk.
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.